We are doing an ongoing study of vivax and falciparum malaria in Peru in the Amazon.    This study is population based and longitudinal.  One of the issues with longitudinal studies is that patients fatigue when studied by multiple blood samples.   This study will determine in normal individuals the role of Salivary IgA antibody in patients before and after treatment for vivax malaria in relation to serum antibody.   We will study MSP3 antigen and the response in the salivary gland in adults initially and compare it to serum antibody.  Once established we will then study children and determine if this method will permit monitoring antibody response to infection .  If it functions this  will permit bloodless sequential monitoring of childrens antibody responses  in this disease.                                                                               

Robert H. Gilman, MD